Proteus presses ahead with pounds 10m rights issue
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.PROTEUS International, the drug research company that recently parted company with UBS as its stockbroker, is pressing ahead with a pounds 10.4m fund-raising despite a precipitous fall in its share price.
Since mid-January, Proteus's price on the Unlisted Securities Market has tumbled from 472p to 290p. The one-for-seven rights issue, underwritten by Allied Provincial Securities, is at 280p a share.
UBS resigned only four months after its appointment following a disagreement over how quickly Proteus would be able to bring its products to the market.
Kevin Gilmore, chairman, said Proteus had wanted to press ahead with the rights issue because of the need to finance annual spending of pounds 7m on research and development, and because there was no guarantee the share price would recover. The money from the issue would help bolster confidence in Proteus. 'It's the performance of the company that will eventually resolve this situation,' he said.
Proteus will receive its first income this year and expects revenue to rise sharply by 1996 when it hopes to be marketing its adjuvant drug, which enhances the immune response of vaccines. Mr Gilmore said Proteus may not need to return to its shareholders for money.
Mr Gilmore and John Pool, his managing director, are not able to take up their rights to 2.2 million shares, so their joint holding will fall from 49.7 to 43.5 per cent.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments